Metronidazol Aurovitas (Metronidazole)

Metronidazole penetrates anaerobic microorganisms and is reduced by their internal electron transport proteins. This reduction creates nitro radical anions that damage DNA and inhibit nucleic acid synthesis, ultimately killing the bacteria or protozoa that cause the infection.

The specific dose and treatment duration of Metronidazol Aurovitas are determined by the prescribing clinician based on the infection type, severity, patient age, weight, and renal or hepatic function. Patients should follow the exact regimen provided by their healthcare professional.

Safety in pregnancy and lactation has not been definitively established for Metronidazol Aurovitas. Healthcare providers weigh potential benefits against possible risks before prescribing it to pregnant or nursing individuals. Women should discuss their situation with a qualified professional.

To request Metronidazol Aurovitas, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metronidazol Aurovitas belongs to the nitroimidazole class, offering broad activity against anaerobic bacteria and certain protozoa. Compared with alternatives such as clindamycin or carbapenems, metronidazole provides a convenient oral option with a well‑characterized safety profile, though drug‑specific resistance patterns and patient factors guide final selection.

Metronidazol Aurovitas should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Metronidazol Aurovitas is taken orally, usually with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include seizures, peripheral neuropathy, severe allergic reactions (including anaphylaxis), Stevens‑Johnson syndrome, pseudomembranous colitis, and liver toxicity. Patients should seek immediate medical attention if they experience neurological symptoms, rash, or signs of severe infection.

Metronidazol Aurovitas is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazole derivatives. Caution is also advised for patients with severe hepatic impairment, those who consume alcohol heavily, and individuals with a history of severe neurological reactions to the drug.